Citation Impact
Citing Papers
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Linkage Map ofEscherichia coliK-12, Edition 10: The Traditional Map
1998
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
2011
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Gonadotropin-releasing hormone analogs and prostatic cancer
1988
A view on drug resistance in cancer
2019 StandoutNature
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Bacterial osmoadaptation: the role of osmolytes in bacterial stress and virulence
2002
New treatment for acute myelogenous leukemia
2014
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Prodrug Strategies in Anticancer Chemotherapy
2007
Linker Technologies for Antibody–Drug Conjugates
2013
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia
2002
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
2014
Antibody targeted drugs as cancer therapeutics
2006
Genome sequence of the endocellular bacterial symbiont of aphids Buchnera sp. APS
2000 StandoutNature
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Interaction of the sensor module of Mycobacterium tuberculosis H37Rv KdpD with members of the Lpr family
2003
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
2004
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
A Bioorthogonal Reaction of N‐Oxide and Boron Reagents
2015 StandoutNobel
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
The angiogenic switch in carcinogenesis
2009
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Human DNA Damage Checkpoint Protein hRAD9 Is a 3′ to 5′ Exonuclease
2000 StandoutNobel
An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
2004
RECIST revisited: A review of validation studies on tumour assessment
2006
Tumor Angiogenesis
2008 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Arming antibodies: prospects and challenges for immunoconjugates
2005
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
2003
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Functions of the gene products of Escherichia coli
1993
Acute Myeloid Leukemia
2015 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes
2008
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Osmosensory signaling in Mycobacterium tuberculosis mediated by a eukaryotic-like Ser/Thr protein kinase
2013 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Antibody therapy for acute myeloid leukaemia
2013
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
2008
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
The Complete Genome Sequence of Escherichia coli K-12
1997 StandoutScience
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
A Genomic Perspective on Protein Families
1997 StandoutScience
Immune Therapy for Cancer
2008
Works of Grant Williams being referenced
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
2003
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
1984
Assessment of the value of confirming responses in clinical trials in oncology
2005
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group
2011
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
2001
The products of the kdpDE operon are required for expression of the Kdp ATPase of Escherichia coli
1992
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
2002
Developing Drugs to Decrease the Toxicity of Chemotherapy
2001
End Points and United States Food and Drug Administration Approval of Oncology Drugs
2003